{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,3]],"date-time":"2024-07-03T00:12:46Z","timestamp":1719965566519},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2024,5,2]],"date-time":"2024-05-02T00:00:00Z","timestamp":1714608000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,5,2]],"date-time":"2024-05-02T00:00:00Z","timestamp":1714608000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Urologie"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1007\/s00120-024-02352-0","type":"journal-article","created":{"date-parts":[[2024,5,2]],"date-time":"2024-05-02T16:02:39Z","timestamp":1714665759000},"page":"653-657","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Botulinumtoxin bei Symptomen des unteren Harntraktes beim Mann (\u201emale LUTS\u201c): Was darf man erwarten?","Botulinum toxin in male lower urinary tract symptoms (LUTS): What can we expect?"],"prefix":"10.1007","volume":"63","author":[{"given":"Sandra","family":"Sch\u00f6nburg","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,5,2]]},"reference":[{"key":"2352_CR1","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1067\/mob.2002.125704","volume":"21","author":"P Abrams","year":"2002","unstructured":"Abrams\u00a0P, Cardozo\u00a0L, Fall\u00a0M et\u00a0al (2002) The Standardisation of Terminology of Lower Urinary Tract Function: Report from the Standardisation Subcommittee of the International Continence Society. Neurourol Urodyn 21:167\u2013178. https:\/\/doi.org\/10.1067\/mob.2002.125704","journal-title":"Neurourol Urodyn"},{"issue":"2","key":"2352_CR2","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1097\/JU.0000000000000525","volume":"203","author":"LM Arrom","year":"2020","unstructured":"Arrom\u00a0LM, Ferrer\u00a0OM, Rubio\u00a0LS et\u00a0al (2020) Treatment Response and Complications after Intradetrusor OnabotulinumtoxinA Injection in Male Patients with Idiopathic Overactive Bladder Syndrome. J\u00a0Urol 203(2):392\u2013397. https:\/\/doi.org\/10.1097\/JU.0000000000000525","journal-title":"J Urol"},{"issue":"6","key":"2352_CR3","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1016\/j.euf.2020.08.015","volume":"7","author":"J Bels","year":"2021","unstructured":"Bels\u00a0J, de Vries\u00a0P, de Beij\u00a0J et\u00a0al (2021) Long-term Follow-up of Intravesical Onabotulinum Toxin\u2014A Injections in Male Patients with Idiopathic Overactive Bladder: Comparing Surgery-na\u00efve Patients and Patients After Prostate Surgery. Eur Urol Focus 7(6):1424\u20131429. https:\/\/doi.org\/10.1016\/j.euf.2020.08.015","journal-title":"Eur Urol Focus"},{"key":"2352_CR4","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1007\/s00120-012-3091-3","volume":"52","author":"T Bschleipfer","year":"2013","unstructured":"Bschleipfer\u00a0T, Bach\u00a0T, Gratzke\u00a0C et\u00a0al (2013) Intraprostatische Injektionstherapien beim benignen Prostatasyndrom. Urologe 52:354\u2013358. https:\/\/doi.org\/10.1007\/s00120-012-3091-3","journal-title":"Urologe"},{"key":"2352_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.tcmj.2015.12.003","volume":"28","author":"J Chen","year":"2016","unstructured":"Chen\u00a0J, Chen\u00a0S, Jiang\u00a0Y, Kuo\u00a0H (2016) Practical points in the medical treatment of overactive bladder and nocturia in the elderly. Tzu Chi Med\u00a0J 28:1\u20135. https:\/\/doi.org\/10.1016\/j.tcmj.2015.12.003","journal-title":"Tzu Chi Med J"},{"key":"2352_CR6","doi-asserted-by":"publisher","unstructured":"Chiang P.H., Chuang Y.C., Huang C.C., Chiang C.P. Pilot study of transperineal injection of dehydrated ethanol in the treatment of prostatic obstruction. Urology 2003; 61(4): p.\u00a0797\u2013801. https:\/\/doi.org\/10.1016\/S0090-4295(02)02514-1","DOI":"10.1016\/S0090-4295(02)02514-1"},{"key":"2352_CR7","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/1471-2490-6-12","volume":"6","author":"YC Chuang","year":"2006","unstructured":"Chuang\u00a0YC, Tu\u00a0CH, Huang\u00a0CC et\u00a0al (2006) Intraprostatic injection of botulinum toxin type\u2014A relieves bladder outlet obstruction in human and induces prostate apoptosis in dogs. BMC Urol 6:12. https:\/\/doi.org\/10.1186\/1471-2490-6-12","journal-title":"BMC Urol"},{"key":"2352_CR8","first-page":"7217","volume":"21","author":"B Chughtai","year":"2014","unstructured":"Chughtai\u00a0B, Dunphy\u00a0C, Lee\u00a0R et\u00a0al (2014) Randomized, double-blind, placebo controlled pilot study of intradetrusor injections of onabotulinumtoxinA for the treatment of refractory overactive bladder persisting following surgical management of benign prostatic hyperplasia. Can J Urol 21:7217\u20137221","journal-title":"Can J Urol"},{"issue":"2","key":"2352_CR9","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1002\/nau.23897","volume":"38","author":"C D\u2019Ancona","year":"2019","unstructured":"D\u2019Ancona\u00a0C, Haylen\u00a0B, Oelke M et\u00a0al The International Continence Society (2019) (ICS) report on the terminology for adult male lower urinary tract and pelvic floor symptoms and dysfunction. Neurourol Urodyn 38(2):433\u2013477. https:\/\/doi.org\/10.1002\/nau.23897","journal-title":"Neurourol Urodyn"},{"issue":"5","key":"2352_CR10","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1016\/j.eururo.2020.06.004","volume":"78","author":"M Drake","year":"2020","unstructured":"Drake\u00a0M, Lewis\u00a0A, Young\u00a0G et\u00a0al (2020) Diagnostic Assessment of Lower Urinary Tract Symptoms in Men Considering Prostate Surgery: A\u00a0Noninferiority Randomised Controlled Trial of Urodynamics in 26 Hospitals. Eur Urol 78(5):701\u2013710. https:\/\/doi.org\/10.1016\/j.eururo.2020.06.004","journal-title":"Eur Urol"},{"issue":"4","key":"2352_CR11","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1080\/2090598X.2019.1662214","volume":"17","author":"AS El-Dakhakhny","year":"2019","unstructured":"El-Dakhakhny\u00a0AS, Gharib\u00a0T, Issam\u00a0A, El-Karamanya\u00a0TM (2019) Transperineal intraprostatic injection of botulinum neurotoxin\u00a0A vs transurethral resection of prostate for management of lower urinary tract symptoms secondary to benign prostate hyperplasia: A\u00a0prospective randomised study. Arab J Urol 17(4):270\u2013278. https:\/\/doi.org\/10.1080\/2090598X.2019.1662214","journal-title":"Arab J Urol"},{"issue":"2","key":"2352_CR12","first-page":"265","volume":"21","author":"MS Faruque","year":"2012","unstructured":"Faruque\u00a0MS, Alam\u00a0MK, Ullah\u00a0MA et\u00a0al (2012) Evaluation of transurethral ethanol ablation of prostate for symptomatic benign prostatic hyperplasia. Mymensingh Med\u00a0J 21(2):265\u2013269","journal-title":"Mymensingh Med J"},{"issue":"2","key":"2352_CR13","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1177\/1756287217742837","volume":"10","author":"M Gacci","year":"2018","unstructured":"Gacci\u00a0M, Sebastianelli\u00a0A, Spatafora\u00a0P et\u00a0al (2018) Best practice in the management of storage symptoms in male lower urinary tract symptoms: a\u00a0review of the evidence base. Ther Adv Urol 10(2):79\u201392. https:\/\/doi.org\/10.1177\/1756287217742837","journal-title":"Ther Adv Urol"},{"issue":"12","key":"2352_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2490-12-1","volume":"4","author":"T Gorgal","year":"2012","unstructured":"Gorgal\u00a0T, Charrua\u00a0A, Silva\u00a0JF et\u00a0al (2012) Expression of apoptosis-regulating genes in the rat prostate following botulinum toxin type\u00a0A injection. BMC Urol 4(12):1. https:\/\/doi.org\/10.1186\/1471-2490-12-1","journal-title":"BMC Urol"},{"issue":"3","key":"2352_CR15","doi-asserted-by":"publisher","first-page":"157","DOI":"10.5152\/tud.2019.82783","volume":"45","author":"C G\u00fcrb\u00fcz","year":"2019","unstructured":"G\u00fcrb\u00fcz\u00a0C, Drake\u00a0M (2019) Where can urodynamic testing help assess male lower urinary tract symptoms? Turk J Urol 45(3):157\u2013163. https:\/\/doi.org\/10.5152\/tud.2019.82783","journal-title":"Turk J Urol"},{"key":"2352_CR16","doi-asserted-by":"publisher","unstructured":"Hald T. Urodynamics in benign prostatic hyperplasia: A\u00a0survey. Prostate 1989; 15 (Suppl.2): 269\u2013277. https:\/\/doi.org\/10.1002\/pros.2990150508","DOI":"10.1002\/pros.2990150508"},{"key":"2352_CR17","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.juro.2017.01.069","volume":"198","author":"S Herschorn","year":"2017","unstructured":"Herschorn\u00a0S, Kohan\u00a0A, Aliotta\u00a0P et\u00a0al (2017) The Efficacy and Safety of OnabotulinumtoxinA or Solifenacin Compared with Placebo in Solifenacin Na\u00efve Patients with Refractory Overactive Bladder: Results from a\u00a0Multicenter, Randomized, Double-Blind Phase\u00a03b Trial. J\u00a0Urol 198:167\u2013175. https:\/\/doi.org\/10.1016\/j.juro.2017.01.069","journal-title":"J Urol"},{"key":"2352_CR18","doi-asserted-by":"publisher","first-page":"498","DOI":"10.3390\/toxins14070498","volume":"14","author":"HC Kuo","year":"2022","unstructured":"Kuo\u00a0HC (2022) Clinical Application of Botulinum Neurotoxin in Lower-Urinary-Tract Diseases and Dysfunctions: Where Are We Now and What More Can We Do? Toxins 14:498. https:\/\/doi.org\/10.3390\/toxins14070498","journal-title":"Toxins"},{"key":"2352_CR19","doi-asserted-by":"publisher","first-page":"6","DOI":"10.4103\/tcmj.tcmj_3_17","volume":"29","author":"C Lee","year":"2017","unstructured":"Lee\u00a0C, Kuo\u00a0H (2017) Current consensus and controversy on the diagnosis of male lower urinary tract symptoms\/benign prostatic hyperplasia. Tzu Chi Med\u00a0J 29:6\u201311. https:\/\/doi.org\/10.4103\/tcmj.tcmj_3_17","journal-title":"Tzu Chi Med J"},{"key":"2352_CR20","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1016\/j.eururo.2012.10.005","volume":"63","author":"M Marberger","year":"2013","unstructured":"Marberger\u00a0M, Chartier-Kastler\u00a0E, Egerdie\u00a0B et\u00a0al (2013) A\u00a0Randomized Double-blind Placebo-controlled Phase\u00a02 Dose-ranging Study of OnabotulinumtoxinA in Men with Benign Prostatic Hyperplasia. Eur Urol 63:496\u2013503. https:\/\/doi.org\/10.1016\/j.eururo.2012.10.005","journal-title":"Eur Urol"},{"issue":"1","key":"2352_CR21","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.juro.2014.02.004","volume":"192","author":"KT McVary","year":"2014","unstructured":"McVary\u00a0KT, Roehrborn\u00a0CG, Chartier-Kastler\u00a0E et\u00a0al (2014) A\u00a0multicenter, randomized, double-blind, placebo controlled study of onabotulinumtoxinA 200\u202fU to treat lower urinary tract symptoms in men with benign prostatic hyperplasia. J\u00a0Urol 192(1):150\u2013156. https:\/\/doi.org\/10.1016\/j.juro.2014.02.004","journal-title":"J Urol"},{"key":"2352_CR22","doi-asserted-by":"publisher","unstructured":"Panicker J., Fowler C., Kessler T. Lower urinary tract dysfunction in the neurological patient: clinical assessment and management. Lancet Neurol 2015; 14: 720\u2013732. https:\/\/doi.org\/10.1016\/S1474-4422(15)00070-8","DOI":"10.1016\/S1474-4422(15)00070-8"},{"key":"2352_CR23","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1111\/j.1464-410X.2012.11593.x","volume":"111","author":"A P\u00f6yh\u00f6nen","year":"2013","unstructured":"P\u00f6yh\u00f6nen\u00a0A, H\u00e4kkinen\u00a0J, Koskim\u00e4ki\u00a0J et\u00a0al (2013) Empirical evaluation of grouping of lower urinary tract symptoms: principal component analysis of Tampere Ageing Male Urological Study data. BJU Int 111:467\u2013473. https:\/\/doi.org\/10.1111\/j.1464-410X.2012.11593.x","journal-title":"BJU Int"},{"issue":"7","key":"2352_CR24","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.1002\/nau.23196","volume":"36","author":"MS Rahnama\u2019I","year":"2017","unstructured":"Rahnama\u2019I\u00a0MS, Marcelissen\u00a0TAT, Brierley\u00a0B et\u00a0al (2017) Long-term compliance and results of intravesical botulinum toxin A injections in male patients. Neurourol Urodynam 36(7):1855\u20131859. https:\/\/doi.org\/10.1002\/nau.23196","journal-title":"Neurourol Urodynam"},{"issue":"6","key":"2352_CR25","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1007\/s00345-018-2193-y","volume":"36","author":"G Robert","year":"2018","unstructured":"Robert\u00a0G, Descazeaud\u00a0A, Karsenty\u00a0G et\u00a0al (2018) Prostatic injection of botulinum toxin is not inferior to optimized medical therapy in the management of lower urinary tract symptoms due to benign prostatic hyperplasia: results of a\u00a0randomized clinical trial. World J Urol 36(6):921\u2013929. https:\/\/doi.org\/10.1007\/s00345-018-2193-y","journal-title":"World J Urol"},{"key":"2352_CR26","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1097\/00005392-200102000-00033","volume":"165","author":"P Rodrigues","year":"2001","unstructured":"Rodrigues\u00a0P, Lucon\u00a0A, Freire\u00a0G, Arap\u00a0S (2001) Urodynamic pressure flow studies can predict the clinical outcome after transurethral prostatic resection. J\u00a0Urol 165:499\u2013502. https:\/\/doi.org\/10.1097\/00005392-200102000-00033","journal-title":"J Urol"},{"key":"2352_CR27","unstructured":"S2e-Leitlinie Diagnostik und Therapie des Benignen Prostatasyndroms (BPS), Registernummer: 043-034, Langversion 5.0, Stand Februar 2023."},{"issue":"Suppl. 3","key":"2352_CR28","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1111\/j.1464-410X.2009.08369.x","volume":"103","author":"C Sexton","year":"2009","unstructured":"Sexton\u00a0C, Coyne\u00a0K, Kopp\u00a0Z et\u00a0al (2009) The overlap of storage, voiding and postmicturition symptoms and implications for treatment seeking in the USA, UK and Sweden: EpiLUTS. BJU Int 103(Suppl. 3):12\u201323. https:\/\/doi.org\/10.1111\/j.1464-410X.2009.08369.x","journal-title":"BJU Int"},{"key":"2352_CR29","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/j.urology.2018.09.016","volume":"123","author":"N Walker","year":"2019","unstructured":"Walker\u00a0N, Syed\u00a0Q, Malde\u00a0S et\u00a0al (2019) Onabotulinum toxin A Injections in Men With Refractory Idiopathic Detrusor Overactivity. Urology 123:242\u2013246. https:\/\/doi.org\/10.1016\/j.urology.2018.09.016","journal-title":"Urology"},{"key":"2352_CR30","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.urols.2014.12.003","volume":"26","author":"C Wang","year":"2015","unstructured":"Wang\u00a0C, Liao\u00a0C, Kuo\u00a0H (2015) Clinical guidelines for male lower urinary tract symptoms associated with non-neurogenic overactive bladder. Urol Sci 26:7\u201316. https:\/\/doi.org\/10.1016\/j.urols.2014.12.003","journal-title":"Urol Sci"}],"container-title":["Die Urologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00120-024-02352-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00120-024-02352-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00120-024-02352-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,2]],"date-time":"2024-07-02T06:02:55Z","timestamp":1719900175000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00120-024-02352-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,2]]},"references-count":30,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["2352"],"URL":"https:\/\/doi.org\/10.1007\/s00120-024-02352-0","relation":{},"ISSN":["2731-7064","2731-7072"],"issn-type":[{"value":"2731-7064","type":"print"},{"value":"2731-7072","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,2]]},"assertion":[{"value":"17 April 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 May 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"S.\u00a0Sch\u00f6nburg gibt an: Referentent\u00e4tigkeit: Allergan, A.M.I., Apogepha, AstraZeneca, Boston Scientific. Beratert\u00e4tigkeit: A.M.I., AstraZeneca, Omega Pharma.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}